<DOC>
	<DOCNO>NCT00210119</DOCNO>
	<brief_summary>Imatinib mesylate standard treatment Chronic myeloid leukaemia , complete cytogenetic response obtain case molecular response concern small part patient . To increase molecular response ratio decide increase imatinib dose limited resistance drug add zoledronate anti tumoral activity increase anti leukemic effect . We plan accrue 37 patient 5 center . We analyse molecular expression BCR-ABL transcript 6 month treatment , safety , duration response , VEGF expression LTgd production .</brief_summary>
	<brief_title>Imatinib Mesylate Zoledronic Acid Patients With Chronic Myeloid Leukaemia Cytogenetic Response Without Molecular Response</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : registration· Chronic myeloid leukaemia Ph+ confirm cytogenetic analysis BCRABL translocation molecular biology· Chronic phase : &lt; 15 % blast cell blood 5 % bone marrow &lt; 30 % blast cells+promyelocyte cell blood bone marrow &lt; 20 % basophil blood &gt; 100.000 platelets· Without extra medullar attempt except hepatosplenomagalia· First line treatment· Biology biochemistry normal levels· Male female &gt; 18 year old· Signed write consent· ECOG &lt; 3At inclusion· Chronic myeloid leukaemia cytogenetic response without molecular response one year treatment imatinib BCRABL transcript detect RTPCR · Other cancer except basocellular cervix carcinoma · Major surgery last 2 week previous inclusion· Women pregnant breastfeeding ( unable use acceptable method avoid pregnancy partner entire study period ) · Dementia alter mental status would prohibit understanding rendering informed consent · Abnormal renal function creatinine clearance &lt; 30 ml/ minuteAccording CockcroftGault : CrCl= [ [ 140age ( year ) ] x weight ( kg ) ] / [ 72 x serum creatinine ( mg/dL ) ] { x 0.85 woman } · Chronic myeloid leukaemia acute phase pas acute phase · Treatment bisphosphonates last 6 month previous inclusion · Intolerance bisphosphonates : hypersensitivity , course dental problem , include tooth mandibular infection ; dental traumatism recent diagnosis previous mandibular osteonecrosis , dental extraction cicatrisation delay necessity set bone evidence · Mandibular surgery last 6 week plan future treatment ( tooth extraction ) · Serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy : diabetes , thyroid pathology , neuropsychiatric illness , myocardial infarction congestive heart failure grade 34 accord `` New York Heart association '' · History psychiatric depressive pathology · HIV positivity know · Inclusion study investigate antineoplastic molecule last 30 day previous inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>imatinib mesylate</keyword>
	<keyword>zoledronate</keyword>
	<keyword>molecular response</keyword>
</DOC>